DSIP
Research OnlyAlso known as: Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide, WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
Research Statistics
Historical sleep peptide with disputed mechanism and inconsistent human evidence.
Research Dossier
Overview
What is DSIP and what does the research say?
Mechanism of Action
The proposed mechanisms of DSIP are based on a mix of human studies from the 1980s and animal research. The peptide’s exact receptor target remains unidentified, and whether it truly exists as an endogenous compound is still debated.
How It Works (Simplified)
DSIP appears to act as a neuromodulator through several interconnected pathways:
Modulates serotonergic neurotransmission to promote natural sleep patterns rather than acting as a sedative. Effects most pronounced in sleep-disturbed individuals.
Activates antioxidant enzymes (SOD, catalase) and stabilizes cell membranes, reducing oxidative damage under various stress conditions.
Interacts with endogenous opioid systems without direct receptor agonism. May stimulate enkephalin release for non-addictive analgesia.
Influences cortisol, growth hormone, and other hormones that affect sleep-wake cycles and stress responses.
Scientific Pathways
Serotonergic Pathway (Sleep Modulation)
DSIP → 5-HT system modulation → Altered sleep architecture
↓
Delta wave enhancement (proposed)Antioxidant Pathway (Stress Protection)
DSIP → Membrane stabilization → Reduced lipid peroxidation → SOD/Catalase activation
↓
Cellular stress protectionKey Research: Nakamura et al. (Japan, 1986) demonstrated serotonin pathway involvement when DSIP’s sleep effects were blocked by 5-HT antagonists. PMID:3492274
Important Limitations
- No specific DSIP receptor has been identified
- Whether DSIP exists endogenously remains controversial (Kovalzon 2006)
- Most studies are from 1980s-1990s with outdated methodology
- High inter-individual variability in response rates
- Blood-brain barrier penetration mechanism unclear
- Research largely abandoned after 1990s in favor of newer sleep medications
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on early human studies: Initial effects on sleep architecture may begin. Some users report improved sleep quality within days. High variability in response noted across studies.
Human studies showed continued improvement in sleep-disturbed individuals. The 'normalizing' rather than sedating effect becomes more apparent. Stress-protective benefits may emerge based on preclinical data.
Swiss follow-up studies reported sustained benefits in some patients. Analgesic effects documented in chronic pain studies within this timeframe. Response variability remains high.
Long-term human data is limited. One 6-month study showed sustained benefits in responders. Optimal treatment duration is unknown. No tolerance or dependence observed.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate DSIP product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining DSIP with other peptides. Based on published research and mechanistic considerations.
Selank
CompatibleBoth are neuropeptides with anxiolytic and stress-protective properties. Selank is better characterized with more consistent research. No interaction studies available.
Semax
CompatibleNon-overlapping primary mechanisms. DSIP focuses on sleep/stress while Semax is primarily nootropic. Theoretical complementary benefits for cognitive recovery.
Epithalon
CompatibleEpithalon targets telomerase and circadian regulation while DSIP affects sleep architecture. Both may influence circadian rhythms through different pathways.
Melatonin
CautionBoth affect sleep-wake cycles. Combining sleep-modulating compounds may have unpredictable effects. Monitor for excessive sedation if used together.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare DSIP
DSIP Calculators
Related Peptides
Alixorexton
ALKS 2680, ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070, N-PEP-12, Renacenz
A porcine brain-derived peptide mixture approved in over 50 countries (Austria, Russia, China, Germany) for stroke, dementia, and traumatic brain injury. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. NOT FDA-approved despite decades of international use. Mixed Phase 3 results but positive meta-analyses and widespread clinical adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin, Cerebral peptides, A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Cortexin
Cortexinum, Polypeptide brain extract, Bovine brain cortex polypeptides
A Russian neuropeptide complex derived from porcine or bovine cerebral cortex, approved in Russia and CIS countries for neurological conditions. Contains low molecular weight polypeptides (1,000-10,000 Da) with proposed neurotrophic and neuroprotective properties. NOT approved by FDA, EMA, or other Western regulatory agencies. Evidence comes primarily from Russian studies with limited Western validation.
Dihexa
PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
N-Acetyl Selank Amidate
NA-Selank, N-Acetyl Selank, Acetyl-Selank-Amidate +1 more
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.